Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
05 September 2019 | Story Prof Francis Petersen (UFS Rector and Vice-Chancellor)

In light of the ongoing violence against women, and recent surge in femicide in South Africa, the University of the Free State (UFS) recommits itself to challenge, fight and eradicate all forms of gender-based violence on its campus and in the country.

The recent rape and murder of 19-year-old Media and Film Studies student at the University of Cape Town (UCT), Uyinene Mrwetyana, and the murder of University of the Western Cape (UWC) student, Jesse Hess, are painful reminders of the pervasive nature of misogyny and patriarchal violence that impedes the freedom of women/womxn in South Africa. The UFS stands in solidarity with UCT and UWC, and all other South African universities that are currently steeped in this national crisis pertaining to gender-based violence.

The UFS perceives this as an enduring manifestation of patriarchy that results in women’s/womxn’s subordination, inequality, and violation of bodily integrity. These horrific events underscore the extent to which attempts to address women’s/womxn’s inequality and gender-based violence nationally, and more pertinently at universities, have failed. Recent discussions have underscored the issue of ‘belonging’ as a concern in Higher Education contexts. Belonging is often couched in the language of ‘access’ and ‘transformation’. However, these terms often provide limited substantive change for students who experience a sense of marginalisation and alienation at South African universities. Decolonisation discourse challenges the nature of hegemonic knowledge production that excludes voices of alterity.

Epistemic violence is central to decolonisation discourse referring to the nature of hegemonic knowledge production that excludes voices of alterity. The extent to which knowledge production manifests in universities is, however, not only white and Western, but also male and masculine. South African universities are therefore confronted again with the urgency of recognising and responding to the issue of women’s/womxn’s subordination, with specific emphasis on their safety and freedom.

The UFS is committed to creating a university space where all our students feel that they belong, by broadening current epistemologies and including women’s/womxn’s voices and lived experiences. More pertinently and in a practical manner, curriculum change should include diverse intellectual perspectives and incorporate an ethics of care in teaching practices. The UFS acknowledges that more must be done as a space of higher learning to investigate the causes that underlie the continuance of sexual violence against women/womxn.

On Friday 6 September 2019, the UFS held a day of mourning, standing in solidarity with other universities in their attempt to respond to the present crisis. In mourning Uyinene and Jesse’s death and all other victims and survivors of gender-based violence, the university will critically self-reflect on the multi-layered demand for transformation and consciousness needed for deep change.

The UFS calls on the Department of Higher Education, civil society, the business sector and all others to actively contribute to efforts that will eradicate gender violence. As the UFS, we call specifically on the City of Bloemfontein, the mayor, members of local government, South Africa Police Service and all inhabitants to assist us in making the city safe for all.

Prof Francis Petersen
Rector and Vice-Chancellor
University of the Free State
5 September 2019


News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept